22 Results

People

  1. Mato
    Mato
  2. Palomba
    Palomba
  3. Abdel-Wahab
    Abdel-Wahab
  4. Roeker
    Roeker
  5. Thompson
    Thompson
  6. Zelenetz
    Zelenetz
  7. Aronson
    Aronson
  8. Babady
    Babady
  9. Islam
    Islam
  10. Kamboj
    Kamboj

Groups

  1. Department of Medicine (20)
  2. Hematologic Malignancies, Division of (19)
  3. Center for Hematologic Malignancies (15)
  4. Adult Leukemia (9)
  5. Lymphoma (8)
  6. Executive Committee, Center for Hematologic Malignancies (3)
  7. GME, Medicine (3)
  8. GSK Faculty (3)
  9. Graduate Medical Education (3)
  10. Hematology-Oncology Fellows (3)
  1. "pirtobrutinib"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (5)
  3. Review (5)
  4. Book Section (1)
  5. Conference Paper (1)
  6. Editorial (1)
  7. Research Letter (1)
Groups
  1. Department of Medicine (20)
  2. Hematologic Malignancies, Division of (19)
  3. Center for Hematologic Malignancies (15)
  4. Adult Leukemia (9)
  5. Lymphoma (8)
  6. Executive Committee, Center for Hematologic Malignancies (3)

More Groups

People
  1. Anthony Mato (9)
  2. Lindsey Roeker (8)
  3. Maria Palomba (6)
  4. Meghan Thompson (3)
  5. Omar Abdel-Wahab (3)
  6. Andrew Zelenetz (2)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (7)
  4. 2022 (5)
  5. 2021 (2)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (5)
  2. Haematologica (2)
  3. Advances in Therapy (1)
  4. Blood (1)
  5. British Journal of Haematology (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. Elsevier Inc. (6)
  2. Elsevier Science, Inc. (2)
  3. Ferrata Storti Foundation (2)
  4. Springer (2)
  5. Wiley Blackwell (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants
    Research Letter

    Kamboj, M.; Laracy, J. C.; Usiak, S.; Babady, N. E.; Yan, J.; Seo, S. K.
    Journal of Infection (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma
    Journal Article

    Wang, M. L.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; Flinn, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Report of consensus panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia on priorities for novel clinical trials
    Conference Paper

    Tam, C. S.; Kapoor, P.; Castillo, J. J.; Buske, C.; Ansell, S. M.; Branagan, A. R.; Kimby, E.; Li, Y.; Palomba, M. L.; Qiu, L.; more...
    W.B. Saunders Co-Elsevier Inc. (2023)

    Fulltext@MSK | Save
  • Future directions in the frontline management of Waldenström macroglobulinemia
    Review

    Buske, C.; Palomba, M. L.
    Hematology/Oncology Clinics of North America (2023)

    Fulltext@MSK | Save
  • Clinical experience with drugs targeting Bruton's Tyrosine Kinase (BTK)
    Book Section

    Aronson, J.; Mato, A. R.; Coombs, C. C.; Islam, P.; Roeker, L. E.; Eyre, T.
    In O'Connor, O. A.; Ansell, S. M.; Seymour, J. F. (Eds.) Precision Cancer Therapies (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed-duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Wierda, W. G.; Pagel, J. M.; Davids, M. S.; Zinzani, P. L.; Lu, Y.; Liu, H.; Shahda, S.; Leow, C. C.; Tam, C. S.; Woyach, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Hill, M.; Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • The potential of pirtobrutinib in multiple B-cell malignancies
    Review

    Jensen, J. L.; Mato, A. R.; Pena, C.; Roeker, L. E.; Coombs, C. C.
    Therapeutic Advances in Hematology (2022)

    Fulltext@MSK | Save